Comparison of the intrinsic vasorelaxant and inotropic effects of the antiarrhythmic agents vernakalant and flecainide in human isolated vascular and cardiac tissues

Journal of Cardiovascular Pharmacology

Volumn 61, Issue 3, 2013, Pages 226-232

  Lynch, Joseph J ^a   Regan, Christopher P ^a   Beatch, Gregory N ^b   Gleim, Gilbert W ^a   Morabito, Christopher J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Cardiome Pharma Corp   (Canada)

Author keywords

antiarrhythmic; atrial fibrillation; flecainide; vernakalant

Indexed keywords

FLECAINIDE; VERNAKALANT;

ARTERY; ARTERY DIAMETER; ARTERY TONE; ARTICLE; COMPARATIVE STUDY; CONCENTRATION RESPONSE; CONTROLLED STUDY; HEART; HEART FUNCTION; HEART HEMODYNAMICS; HEART MUSCLE; HEART MUSCLE CONTRACTILE FORCE; HEART VENTRICLE CONTRACTILITY; HUMAN; HUMAN TISSUE; INOTROPISM; MUSCLE ISOMETRIC CONTRACTION; PRIORITY JOURNAL; RESISTANCE BLOOD VESSEL; SUBCUTANEOUS RESISTANCE ARTERY; VASCULAR TISSUE; VASODILATATION; VENTRICULAR TRABECULAR MUSCLE;

ANISOLES; ANTI-ARRHYTHMIA AGENTS; ARTERIES; CARDIOTONIC AGENTS; CARDIOTOXINS; FLECAINIDE; HEART VENTRICLES; HUMANS; MYOCARDIAL CONTRACTION; OSMOLAR CONCENTRATION; PYRROLIDINES; SKIN; SODIUM POTASSIUM CHLORIDE SYMPORTER INHIBITORS; VASCULAR RESISTANCE; VASODILATION; VASODILATOR AGENTS;

EID: 84875228470     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31827afd29     Document Type: Article

References (39)

1. Schlepper M. Cardiodepressive effects of antiarrhythmic drugs. Eur Heart J. 1989;10(suppl E):73-80.
2. Camm AJ. Safety considerations in the pharmacological management of atrial fibrillation. Int J Cardiol. 2008;127:299-306.
3. Bash LD, Buono JL, Davies GM, et al. Systemic review and meta-analysis of the efficacy of cardioversion by vernakalant and comparators in patients with atrial fibrillation. Cardiovasc Drugs Ther. 2012;26: 167-179.
4. Roy D, Pratt CM, Torp-Pedersen C, et al. Vernakalant hydrochloride for rapid conversion of atrial fibrillation. A phase 3, randomized, placebocontrolled trial. Circulation. 2008;117:1518-1525.
5. Pratt CM, Roy D, Torp-Pedersen C, et al. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation. J Am Coll Cardiol. 2010;106:1277-1283.
6. Camm AJ, Capucci A, Hohnloser SH, et al. A randomized activecontrolled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol. 2011; 57:313-321.
7. Kowey PR, Dorian P, Mitchell LB, et al. Vernakalant hydrochloride for the rapid conversion of atrial fibrillation after cardiac surgery: a randomized, double-blind, placebo-controlled trial. Circ Arrhythm Electrophysiol. 2009; 2:652-659.
8. Fedida D, Orth PM, Chen JY, et al. The mechanism of atrial antiarrhythmic action of RSD1235. J Cardiovasc Electrophysiol. 2005;16:1227-1238.
9. Fedida D. Vernakalant (RSD1235): a novel, atrial-selective antifibrillatory agent. Expert Opin Investig Drugs. 2007;16:519-532.
10. Mao Z, Wheeler JJ, Townsend R, et al. Population pharmacokinetic- pharmacodynamic analysis of vernakalant hydrochloride injection (RSD1235) in atrial fibrillation or atrial flutter. J Pharmacokinet Pharmacodyn. 2011;38:541-562.
11. Duggan ST, Scott LJ. Intravenous vernakalant. A review of its use in the management of recent-onset atrial fibrillation. Drugs. 2011;71: 237-252.
12. Blomström-Lundqvist C, Blomström P. Safety and efficacy of pharmacologic cardioversion of atrial fibrillation using intravenous vernakalant, a new antiarrhythmic drug with atrial selectivity. Expert Opin Drug Saf. 2012;11:671-679.
13. Josephson MA, Kaul S, Hopkins J, et al. Hemodynamic effects on intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. Am Heart J. 1985;109:41-45.
14. Legrand V, Materne P, Vandormael M, et al. Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy. Eur Heart J. 1985; 6:664-671.
15. Cohen AA, Daru V, Covelli G, et al. Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction. Am Heart J. 1985;110:1193-1196.
16. Santinelli V, Arnese M, Oppo I, et al. Effects of flecainide and propafenone on systolic performance in subjects with normal cardiac function. Chest. 1993;103:1068-1073.
17. Lewis TV, Cooper BA, Dart AM, et al. Responses to endothelin-dependent agonists in subcutaneous arteries excised from hypercholesterolaemic men. Br J Pharmacol. 1998;124:222-228.
18. Morris STW, McMurray JJV, Spiers A, et al. Impaired endothelial function in isolated human uremic resistance arteries. Kidney Int. 2001; 60:1077-1082.
19. Rizzoni D, Porteri E, De Cuiceis C, et al. Lack of prognostic role of endothelial dysfunction in subcutaneous small resistance arteries of hypertensive patients. J Hypertens. 2006;24:867-873.
20. DeCuiceis C, Porteri E, Rizzoni D, et al. Effects of weight loss on structural and functional alterations of subcutaneous small arteries in obese patients. Hypertension. 2011;58:29-36.
21. Ferry DR, Glossman H, Kaumann AJ. Relationship between the stereoselective negative inotropic effects of verapamil enantiomers and their binding to putative calcium channels in human heart. Br J Pharmacol. 1985;84:811-824.
22. Godfraind T, Egleme C, Finet M, et al. The actions of nifedipine and nisoldipine on the contractile activity of human coronary arteries and human cardiac tissue in vitro. Pharmacol Toxicol. 1987;61:79-84.
23. Koglin J, Bohm M, von Scheidt W, et al. Antiadrenergic effect of carbachol but not of adenosine on contractility in the intact human ventricle in vivo. J Am Coll Cardiol. 1994;23:678-683.
24. Du XY, Schoemaker RG, Bos E, et al. Characterization of the positive and negative inotropic effects of acetylcholine in the human myocardium. Eur J Pharmacol. 1995;284:119-127.
25. Giessler C, Dhein S, Ponicke K, et al. Muscarinic receptors in the failing human heart. Eur J Pharmacol. 1999;375:197-202.
26. Ogletree ML, Sprung J, Moravec CS. Effects of remifentanil on the contractility of failing human heart muscle. J Cardiothorac Vasc Anesth. 2005;19:763-767.
27. Cremers B, Flesch M, Sudkamp M, et al. Effects of the novel T-type calcium channel antagonist mibefradil on human myocardial contractility in comparison with nifedipine and verapamil. J Cardiovasc Pharmacol. 1997;29:692-696.
28. Perez-Vizcaino F, Duarte J, Tamargo J. Effects of flecainide on isolated vascular smooth muscles of rat. Br J Pharmacol. 1991;104:726-730.
29. Del Pozo BF, Perez-Vizcaino F, Fernandez C, et al. Effects of several class I antiarrhythmic drugs on isolated rat aortic vascular smooth muscle. Gen Pharmacol. 1997;29:539-543.
30. Cogolludo AL, Perez-Vizcaino F, Tamargo J. Antagonism by class I antiarrhythmic drugs of levocromakalim-induced relaxation in isolated rat aorta. J Pharmacol Exp Therap. 1998;287:81-86.
31. Omar HA, Rhodes LA, Ramirez R, et al. Alteration of human placental vascular tone by antiarrhythmic medications in vitro. J Cardiovasc Electrophysiol. 1996;7:1197-1203.
32. Schulze JJ, Knops J. Effects of flecainide on contractile force and electrophysiologic parameters in cardiac muscle. Arzneim-Forsch. 1982;32: 1025-1029.
33. Brown BS, Calzadilla SV, Diemer MJ, et al. Antiarrhythmic, electrophysiologic and hemodynamic effects of ACC-9358. J Pharmacol Exp Therap. 1987;243:1225-1234.
34. Josephson MA, Ikeda N, Singh BN. Effects of flecainide on ventricular function: clinical and experimental correlations. Am J Cardiol. 1984;53: 95B-100B.
35. Kihara Y, Inoko M, Hatakeyama N, et al. Mechanisms of negative inotropic effects of class IC antiarrhythmic agents: comparative studies of the effects of flecainide and pilsicainide on intracellular calcium handling in dog ventricular myocardium. J Cardiovasc Pharmacol. 1996;27: 42-51.
36. Goy J-J, Maendly R, Grbic M, et al. Cardioversion with flecainide in patients with atrial fibrillation of recent onset. Eur J Clin Pharmacol. 1985;27:737-738.
37. Suttorp MJ, Kingma JH, Lie-A-Huen L, et al. Intravenous flecainide versus verapamil for acute cardioversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. Am J Cardiol. 1989;63:693-696.
38. Follmer CH, Cullinan CA, Colatsky TJ. Differential block of cardiac delayed rectifier current by class IC antiarrhythmic drugs: evidence for open channel block and unblock. Cardiovasc Res. 1992;26:1121-1130.
39. Tamargo J, Caballero R, Gomez R, et al. Pharmacology of cardiac potassium channels. Cardiovasc Res. 2004;62:9-33.